Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Abstract

With proteasome inhibitors (PIs) becoming clinically available since 2003, outcomes for patients with multiple myeloma (MM) have dramatically changed, improving quality of life and survival. Despite the impressive treatment success, however, almost all MM patients who initially respond to these PIs eventually develop resistance. Furthermore, a portion of MM patients is inherently unresponsive to the PIs. Extensive mechanistic investigations identified several non-proteasomal signaling pathways suspected to be linked to the PI resistance, for which several excellent reviews are currently available. On the other hand, it is still unclear how cancer cells under high PI environments adapt to spare proteasome activity essential for survival and proliferation regardless of cancer evolution stages. This review outlines current progress towards understanding the proteasomal adaptations of cells in response to PI treatment to maintain necessary proteasome activity. A better understanding of cellular proteasomal changes in response to the PIs could provide a rationale to develop new therapeutics that could be used to overcome resistance to existing PI drugs.

Keywords

Constitutive proteasome / immunoproteasome / carfilzomib / bortezomib / drug resistance

References

[1] Park JE,Jun Y,Kim KB.Next-generation proteasome inhibitors for cancer therapy.Transl Res2018;198:1-16 PMCID:PMC6151281

[2] Hanahan D.The Hallmarks of Cancer.Cell2000;100:57-70

[3] Luo J,Elledge SJ.Principles of cancer therapy: oncogene and non-oncogene addiction.Cell2009;136:823-37 PMCID:PMC2894612

[4] Furukawa Y.Molecular basis of clonal evolution in multiple myeloma.Int J Hematol2020;111:496-511

[5] Schrader J,Mata RA.The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.Science2016;353:594-8

[6] Carmony K,Kim KB.High-resolution snapshots of proteasome inhibitors in action revise inhibition paradigms and inspire next-generation inhibitor design.Chembiochem2016;17:2115-7 PMCID:PMC5192039

[7] Suzuki E,Deu E.Molecular mechanisms of bortezomib resistant adenocarcinoma cells.PLoS One2011;6:e27996 PMCID:PMC3245226

[8] Yang Y,Gu H,Cai Z.Emerging agents and regimens for multiple myeloma.J Hematol Oncol2020;13:150 PMCID:PMC7654052

[9] Liu J,Mi L.Union for China Lymphoma Investigators of the Chinese Society of Clinical OncologyUnion for China Leukemia Investigators of the Chinese Society of Clinical OncologyIncidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016.J Hematol Oncol2019;12:136 PMCID:PMC6905074

[10] Bergsagel PL.Where we were, where we are, where we are going: progress in multiple myeloma.Am Soc Clin Oncol Educ Book2014;199-203

[11] Kumar S.Many facets of bortezomib resistance/susceptibility.Blood2008;112:2177-8

[12] Richardson PG,Berenson J.A phase 2 study of bortezomib in relapsed, refractory myeloma.N Engl J Med2003;348:2609-17

[13] Herndon TM,Kaminskas E.U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.Clin Cancer Res2013;19:4559-63

[14] Stewart AK,Dimopoulos MA.ASPIRE InvestigatorsCarfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.N Engl J Med2015;372:142-52

[15] Vij R,Kaufman JL.An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.Blood2012;119:5661-70 PMCID:PMC4123327

[16] Verbrugge SE,Assaraf YG.Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors.Exp Hematol Oncol2013;2:2 PMCID:PMC3560160

[17] Verbrugge SE,Dijkmans BA.Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.J Pharmacol Exp Ther2012;341:174-82

[18] McConkey DJ.Mechanisms of proteasome inhibitor action and resistance in cancer.Drug Resist Updat2008;11:164-79

[19] Ao L,Kim D.Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib.Mol Pharm2012;9:2197-205 PMCID:PMC3473138

[20] Leung-Hagesteijn C,Cheung G.Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.Cancer Cell2013;24:289-304 PMCID:PMC4118579

[21] Nikesitch N.Molecular mechanisms in multiple myeloma drug resistance.J Clin Pathol2016;69:97-101 PMCID:PMC4752637

[22] Niewerth D,Assaraf YG,Kaspers GJ.Molecular basis of resistance to proteasome inhibitors in hematological malignancies.Drug Resist Updat2015;18:18-35

[23] Niewerth D,Assaraf YG.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.J Hematol Oncol2014;7:7 PMCID:PMC3896789

[24] Deshaies RJ.Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.BMC Biol2014;12:94 PMCID:PMC4226866

[25] Kraus M,Geurink PP.The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.Haematologica2015;100:1350-60 PMCID:PMC4591768

[26] Mirabella AC,Downey SL.Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.Chem Biol2011;18:608-18 PMCID:PMC3134264

[27] Kuhn DJ,Chen Q,Orlowski M.Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.Blood2009;113:4667-76 PMCID:PMC2680370

[28] Li X,Sprangers R.Effect of noncompetitive proteasome inhibition on bortezomib resistance.J Natl Cancer Inst2010;102:1069-82

[29] Lee MJ,Park JE,Lee W.H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth.Sci Rep2019;9:4089 PMCID:PMC6411724

[30] Oerlemans R,Assaraf YG.Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.Blood2008;112:2489-99

[31] Lü S,Song X.Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.J Pharmacol Exp Ther2008;326:423-31

[32] Groll M,Ploegh HL.Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.Structure2006;14:451-6

[33] Franke NE,Assaraf YG.Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.Leukemia2012;26:757-68

[34] Allmeroth K,Kroef V,Müller RU.Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma.Leukemia2021;35:887-92 PMCID:PMC7932915

[35] Shi CX,Bruins LA.Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity.Mol Cancer Res2020;18:1453-64 PMCID:PMC7541608

[36] Brünnert D,Stühmer T.Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.Biochim Biophys Acta Mol Basis Dis2019;1865:1666-76

[37] Kortuem KM,Bruins L.Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients.Blood Cancer J2016;6:e397 PMCID:PMC4771964

[38] Walker BA,Wardell CP.Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.J Clin Oncol2015;33:3911-20 PMCID:PMC6485456

[39] Egan JB,Tembe W.Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.Blood2012;120:1060-6 PMCID:PMC3412329

[40] Barrio S,Da-Viá M.Spectrum and functional validation of PSMB5 mutations in multiple myeloma.Leukemia2019;33:447-56

[41] Huber EM,Groll M.Bortezomib-resistant mutant proteasomes: structural and biochemical evaluation with carfilzomib and ONX 0914.Structure2015;23:407-17

[42] Tsvetkov P,Zhao J.Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome.Elife2015;4:e08467 PMCID:PMC4551903

[43] Besse A,Rasche L.Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.Leukemia2018;32:391-401 PMCID:PMC5808083

[44] Lü S,Yang J.Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.Exp Hematol2008;36:1278-84

[45] Wu YX,Saitsu H.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.Oncotarget2016;7:77622-34 PMCID:PMC5363609

[46] Shuqing L,Chongmei H,Wang J.Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.Exp Hematol2011;39:1117-8

[47] Wei W,Jiang Q.PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer.Int J Biol Markers2018;33:102-8

[48] Chondrogianni N,Pemberton AJ,Rivett AJ.Overexpression of proteasome beta5 assembled subunit increases the amount of proteasome and confers ameliorated response to oxidative stress and higher survival rates.J Biol Chem2005;280:11840-50

[49] Tsvetkov P,Jin D.Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.Proc Natl Acad Sci U S A2017;114:382-7 PMCID:PMC5240730

[50] Acosta-Alvear D,Wild T.Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Elife2015;4:e08153 PMCID:PMC4602331

[51] Song Y,Ray A.Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Oncogene2017;36:5631-8 PMCID:PMC5705032

[52] Carmony K, Sharma LK, Lee DM, Park JE, Lee W, Kim KB. Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.Chembiochem2015;16:284-92 PMCID:PMC4415169

[53] Busse A,Na IK.Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.Cancer2008;112:659-70

[54] Niewerth D,Jansen G.Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.J Hematol Oncol2016;9:82 PMCID:PMC5011854

[55] Woodle ES,Brailey P.Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.Am J Transplant2020;20:399-410 PMCID:PMC6984988

[56] Klare N,Janek K,Dahlmann B.Intermediate-type 20 S proteasomes in HeLa cells: "asymmetric" subunit composition, diversity and adaptation.J Mol Biol2007;373:1-10

[57] Guillaume B,Stroobant V.Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.Proc Natl Acad Sci U S A2010;107:18599-604 PMCID:PMC2972972

[58] Fabre B,Delobel J.Subcellular distribution and dynamics of active proteasome complexes unraveled by a workflow combining in vivo complex cross-linking and quantitative proteomics.Mol Cell Proteomics2013;12:687-99 PMCID:PMC3591661

[59] Gohlke S,Tsokos M.Adult human liver contains intermediate-type proteasomes with different enzymatic properties.Ann Hepatol2014;13:429-38

[60] Drews O,Zong C.Mammalian proteasome subpopulations with distinct molecular compositions and proteolytic activities.Mol Cell Proteomics2007;6:2021-31

[61] Gomes AV,Wang Y.Contrasting proteome biology and functional heterogeneity of the 20 S proteasome complexes in mammalian tissues.Mol Cell Proteomics2009;8:302-15 PMCID:PMC2634581

[62] Kloss A,Ludwig A.Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors.Cardiovasc Res2010;85:367-75

[63] Pelletier S,Berkers CR,Heck AJ.Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry.Mol Biosyst2010;6:1450-3

[64] Zheng J,Bizzozero OA.Changes in 20S subunit composition are largely responsible for altered proteasomal activities in experimental autoimmune encephalomyelitis.J Neurochem2012;121:486-94 PMCID:PMC3323733

[65] Gohlke S,Textoris-Taube K.Molecular alterations in proteasomes of rat liver during aging result in altered proteolytic activities.Age (Dordr)2014;36:57-72 PMCID:PMC3889881

[66] Parlati F,Aujay M.Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome.Blood2009;114:3439-47

[67] Dahlmann B,Kuehn L,Kloetzel PM.Different proteasome subtypes in a single tissue exhibit different enzymatic properties.J Mol Biol2000;303:643-53

[68] Dahlmann B,Kloetzel PM.Subtypes of 20S proteasomes from skeletal muscle.Biochimie2001;83:295-9

[69] Lee MJ,Yoo J.Development of novel epoxyketone-based proteasome inhibitors as a strategy to overcome cancer resistance to Carfilzomib and Bortezomib.J Med Chem2019;62:4444-55 PMCID:PMC7675178

[70] Lü S,Chen Z.Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.Exp Hematol2009;37:831-7

[71] Fuchs D,Opelz G,Naujokat C.Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.J Cell Biochem2008;103:270-83